AstraZeneca blood clot treatment meets trial endpoint
By Frank Prenesti
Date: Friday 16 Sep 2022
(Sharecast News) - AstraZeneca on Friday said its Danicopan add-on anti blood-clotting drug had met a primary endpoint in a phase III trial.
The company said the treatment for paroxysmal nocturnal haemoglobinu (PNH) - a rare, chronic, progressive and potentially life-threatening blood disorder - showed positive high-level results in the trial.
PNH is characterised by red blood cell destruction within blood vessels (also known as intravascular haemolysis) and white blood cell and platelet activation, which can result in thrombosis, or blood clots.
Reporting by Frank Prenesti at Sharecast.com
Email this article to a friend
or share it with one of these popular networks:
You are here: news
10 Lower Thames St,
London EC3R 6EN